With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle

By Reiji Anasako As the Japanese SGLT2 inhibitor market starts to get on a growth track, competition in the crowded space is expected to heat up particularly among the top three products. First-in-class Suglat (ipragliflozin) is now closely trailed by...read more